Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer (Q39407582)

11 September 2017

Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer (English)

1 reference

11 September 2017

1 reference

1 reference

1 reference

Chloe E Atreya

1

1 reference

11 September 2017

Gregory S Ducker

2

1 reference

11 September 2017

Morris E Feldman

3

1 reference

11 September 2017

Emily K Bergsland

4

1 reference

11 September 2017

Robert S Warren

5

1 reference

11 September 2017

Kevan M Shokat

6

1 reference

11 September 2017

24 January 2012

1 reference

Investigational New Drugs

11 September 2017

1 reference

11 September 2017

30

1 reference

11 September 2017

6

1 reference

11 September 2017

2219-2225

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-012-9793-y

11 September 2017

0 references

cites work

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Rapamycin passes the torch: a new generation of mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Colorectal cancer: mutations in a signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Incidence, mechanism and prognostic value of activated AKT in pancreas cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

EGFR-targeting drugs in combination with cytotoxic agents: from bench to bedside, a contrasted reality

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-012-9793-Y

Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.

21 January 2018

1 reference

12 December 2020

Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor

1 reference

12 December 2020

The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.

1 reference

12 December 2020

Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts

1 reference

12 December 2020

10.1007/S10637-012-9793-Y

Identifiers

DOI

1 reference

11 September 2017

1 reference